Objective: To test the predictive accuracy of the Framingham Risk Score for Stroke (FRS-S) in HIV-infected (HIV1) vs HIV-uninfected (HIV2) men.
The Framingham Risk Score for Stroke (FRS-S) was developed in the early 1990s to identify individuals at substantially increased long-term stroke risk. The score provided impetus for risk factor modification and drew attention to individuals who were at risk of stroke due to borderline levels of multiple factors. 1 In the early 1990s, survival of people with HIV infection was limited, and the Framingham Heart Study Cohort, in whom the FRS-S was developed, was not tested for HIV serostatus.
With the advent of highly active antiretroviral therapy (HAART) and longer survival of HIVinfected (HIV1) individuals, the relationships among chronic HIV infection, HAART use, and vascular disease have become increasingly important. [2] [3] [4] [5] [6] The influence of HIV on long-term stroke risk remains unresolved 7211 even though .50% of all prevalent HIV cases in the United States will be older than 50 years by 2015. 12 Longitudinal studies that prospectively ascertain the effect of HIV on stroke risk in the HAART era are not reported. 5 Here, we test the long-term predictive value of the FRS-S in a large prospectively followed cohort of HIV1 vs HIV-uninfected (HIV2) men who have sex with men (MSM). First, we compare the baseline characteristics of the Framingham cohort vs the Multicenter AIDS Cohort Study (MACS) participants for important stroke risk factor differences. Second, we report the stroke incidence in HIV1 and HIV2 men and determine whether the FRS-S 10 years earlier differed by HIV serostatus among participants with strokes. Finally, as a separate analysis, we calculate the FRS-S at the beginning of the HAART era for all MACS participants and compare it between HIV1 and HIV2 groups.
METHODS Standard protocol approvals, registrations, and patient consents. The MACS was approved by the Institutional Review Board at each study site. Each participant provided his own informed consent to participate in the MACS.
Cohort. The MACS began in 1984 to study the natural history of AIDS. The enrollment, recruitment, and goals of the MACS have been reported. 13, 14 MSM were recruited in Baltimore, Chicago, Los Angeles, and Pittsburgh. Cumulative enrollment is now at .7,000 participants. MSM were chosen because they represented a group at high risk of AIDS and could reliably participate in a longitudinal follow-up study. The HIV status of the men at enrollment was unknown. MSM who remained HIV2 served as a comparison group in the present study.
MACS participants are followed every 6 months via standardized in-person interviews, clinical assessments, neuropsychological screening tests, and laboratory evaluation, including measurements of HIV viral load and T-cell subsets (Roche ultrasensitive assay, ,50 copies/mL, and standardized and qualitycontrolled flow cytometry). 13 By late 1996, HAART was initiated by .50% of all participants, considered as the beginning of the HAART era. 15 Stroke events during a 15-year period of the HAART era (July 1, 1996 to June 30, 2011) were used here.
Definition of stroke. Stroke was ascertained by either self-report at the study visit, prospective active reporting by participants between visits, review of causes of death, or ad hoc when reviewing medical records to confirm other diagnoses. At each MACS visit, participants were asked whether they were diagnosed with stroke since their last visit, and, in April 2004 through March 2005, they were asked about lifetime history of stroke. Hospitalizations and diagnoses for vascular and neurologic problems are continuously monitored. Events are recorded using ICD-9 codes. Reported strokes were followed up by each study site's investigators, including neurologists, via correspondence to the participant's physician.
Death of MACS participants is also continuously monitored. For deaths that were reported by the participant's contact (e.g., partner, physician), death certificates were ascertained and systematically searched for the diagnosis of stroke. Deaths in the MACS are also captured and verified via the National Death Index, Social Security Death Index, credit databases, and scanning of obituaries. Medical records before death were requested. Fatal stroke was defined as a stroke with a reported death within 30 days after the date of first presentation of stroke.
Any event that fit the definition of "silent stroke," defined as imaging findings representative of stroke that were not correlated with clinical symptoms of stroke, were excluded. Self-reported stroke events that could not be confirmed were included, and sensitivity analyses were performed (table e-1 on the Neurology ® Web site at www.neurology.org).
Framingham Risk Score for Stroke. The original FRS-S was sex-specific and based on 36 calendar years of follow-up of 2,372 men and 3,362 women aged 55 to 84 years. 1 There were 213 strokes in men and 259 strokes in women in the Framingham Heart Study's original cohort. The distribution of events diagnosed in men was atherothrombotic brain infarction (46%), TIA only (24%), cerebral embolus (19%), intracerebral hemorrhage (5%), subarachnoid hemorrhage (4%), and other (2%). Points for sex-specific FRS-S were ascribed based on 8 baseline risk factors, identified via Cox proportional hazards regression models: age, systolic blood pressure (mm Hg), antihypertensive therapy, diabetes mellitus, cigarette smoking, atrial fibrillation on ECG, left ventricular hypertrophy on ECG, and history of previously diagnosed cardiovascular disease (table e-2). Cardiovascular disease in the original score included coronary heart disease, history of myocardial infarction, angina pectoris, coronary insufficiency, cardiac failure, and intermittent claudication.
Vascular risk factor definitions. In the MACS, risk factors for stroke were defined according to the Framingham Study whenever possible. For participants who were younger than 55 years, the number of points ascribed for age was zero. Diabetes mellitus was defined as 1) measured fasting glucose levels $126 mg/dL, 2) measured nonfasting glucose levels $200 mg/dL when fasting samples were unavailable, or 3) self-reported diagnosis of diabetes treated with medications. Diabetes was ascertained at study entry and during regular study visits after April 1, 1999 . Cigarette smokers were current smokers. Consistent with the FRS-S, former cigarette smokers were not given risk points. Specific cardiac conditions used in the original FRS were not regularly evaluated clinically by MACS investigators. ECGs were also not performed as part of the MACS. It was assumed here that no MACS participants had atrial fibrillation or left ventricular hypertrophy; therefore, no MACS participants received points for these conditions. However, within the MACS, participants were asked to report their lifetime history between April 2004 and March 2005-and follow-up information on subsequent visits-on whether or not they had experienced 1) myocardial infarction, 2) angina or chest pain caused by the heart, and 3) congestive heart failure. Participants who responded affirmatively to these questions were ascribed the 3 points for cardiovascular disease defined in the FRS-S (table e-1). All other participants were ascribed zero points. The FRS-S risk score conversion to the 10-year predicted risk of stroke is based on the percentage points derived from the original Framingham cohort. 1 Statistical analysis. Participants with prevalent stroke at the time of study entry or stroke in the pre-HAART era were excluded. Among participants with a first-ever stroke during the HAART era, FRS was calculated using risk factors and characteristics from the study visit closest to 10 years before the date of the stroke event. The algorithm provided by the FRS cohort was used (table e-1). Participants in whom risk factor information was missing were considered not to have the risk factor of interest.
As a second measure of stroke risk, calculation of the baseline FRS-S among the entire MACS cohort was performed and compared between HIV1 and HIV2 participants. This was done on all MACS participants, whether they had a stroke event or not, and calculated at the beginning of the HAART era (July 1, 1996) or, if the participant entered the MACS afterward, at the participant's first date of study entry in the HAART era.
Comparison between groups was performed using the Wilcoxon rank sum tests and 2-sample binomial tests for proportions. To reconstruct the FRS-S in the MACS, Cox proportional hazards models were used, stratified by serostatus and combined using serostatus as a binary predictor. The date of data censoring was death, study dropout, or the last followup visit of the participant on or before June 30, 2011. RESULTS There were 3,945 participants (1,776 HIV1 and 2,169 HIV2) in the MACS during the study timeframe. The baseline characteristics of this cohort and incidence of all neurologic disease have been reported 7 and are provided by stroke and HIV serostatus in table 1. There were 114 strokes in MACS participants recorded, including 19 fatal strokes among HIV1 participants (n 5 12) and HIV2 participants (n 5 7). The stroke events occurred throughout the study observation period (figure e-1).
There were 94 first-ever strokes among 57 HIV1 and 37 HIV2 participants with an incidence rate of first-ever stroke of 1.7/1,000 person-years in HIV2 and 3.3/1,000 person-years in HIV1 participants (table 1). The median age at the time of first stroke diagnosis was 55.6 years (range 34.5-8.5 years). Among HIV1 participants, the median age of first stroke was 51.4 compared with 61.8 years in HIV2 participants (p , 0.0001). A total of 70 (74%) were enrolled in the MACS for $10 years before their first stroke event. Among HIV1 participants with first-ever stroke, 52 (91%) occurred while the participant was taking HAART. CD4 count within 60 days before the stroke event was available for 42 of 57 HIV1 participants with stroke (mean 484 cells/mL, range 17-1,256). Among this group, 8 had a CD4 count ,200 cells/mL of whom 7 reported being on HAART.
For HIV1 participants with stroke, the FRS-S 10 years before stroke, for 10-year prediction of stroke, averaged 4.9% (range 0%-15%) compared with HIV2 participants with stroke whose baseline FRS-S averaged 6.6% (range 3%-26%) (p , 0.04). When considering only the subgroup of MACS participants who were enrolled in the cohort study for 10 years or longer, the difference in mean FRS-S between HIV1 and HIV2 participants was still significant (4.0% vs 5.9%, p , 0.02). Notably, 3 HIV1 participants with strokes and more than 10 years of follow-up had an FRS-S predicted risk of zero.
The distribution of risk factors for HIV1 and HIV2 men with stroke events is reported in figure 1 . Overall, HIV1 participants were more likely to be younger and smoke cigarettes. HIV2 participants were marginally more likely to have hypertension. The distribution of history of diabetes and history of myocardial infarction was similar between HIV1 and HIV2 men with strokes. In the entire cohort of HIV1 men without a stroke (median and mean age at first visit during the HAART era 41 years), the mean 10-year predicted risk of stroke was 4.11% (range 0%-26%) vs 4.05% (0%-22%) in HIV2 men (median and mean age 43 years) (p , 0.02). In participants without known stroke, hypertension and cigarette smoking were more likely among HIV1 men (figure 2).
In the analysis of baseline stroke prediction, the association between stroke and traditionally measured risk factors in the FRS-S was similar between the Framingham cohort participants and the MACS participants, but there was a significant added risk of HIV status among HIV1 MACS participants (p , 0.0001, table 2). DISCUSSION Several studies have suggested an increased risk of stroke in HIV1 adults, 4, 9, 10, 16218 but prospectively followed HIV1 individuals over $10 years with incident stroke have not previously been available. Many studies of HIV1 adults are limited to small numbers of stroke, 9, 10, 16, 19, 20 and none has had the opportunity to compare baseline risk with long-term incidence of stroke. The comparison of baseline risk and long-term outcome remains of critical importance to HIV1 individuals. Traditional scores for risk prediction appear to be insufficient to accurately inform long-term cerebrovascular health status in chronic HIV infection. We observed a higher incidence of first-ever strokes in HIV1 vs HIV2 participants (3.3 vs 1.7/1,000 person-years); however, the average 10-year FRS-S predicted risk at baseline was lower in HIV1 vs HIV2 subjects (4.9% vs 6.6%). Remodeling of the baseline stroke risk in the MACS demonstrates that HIV adds a significant risk of stroke.
There are several reasons that the FRS-S may have underestimated stroke risk in HIV1 men in this study. Risk difference using the FRS-S between HIV1 and HIV2 men may be partly accounted for by the younger onset of stroke in HIV1 men therefore leading to lower FRS-S point calculation at 10 years before the event. The original FRS-S was designed in men aged 55 to 84 years and was not modeled for young-onset stroke prediction. In the current study, the median age for stroke was in the fifth and sixth decades of life for both HIV1 and HIV2 MSM.
HIV1 individuals may have unique risk factors for stroke that are measurable and can therefore lead to adjustment in their FRS-S. One study from Spain 10 found that high alcohol intake, a history of a diagnosis of AIDS, and fewer months on HAART increased the risk of stroke, although only 25 patients with stroke were identified. HIV infection itself may portend a higher stroke risk, even when accounting for demographic and traditional stroke risk factors. Most studies in high-income settings suggest that HIV increases stroke risk (table 3) . 4, 9, 10, 16224 In South Africa, however, most studies report similarities in patient characteristics and stroke incidence between HIV1 and HIV2 groups. 19221 The reasons for increased rates of stroke among HIV1 men could include such mechanisms as chronic inflammation leading to atherogenic tendency of the endothelium, remodeling of the intracranial and carotid vasculature, and higher frequency of circulating inflammatory markers. 22, 25227 In the multinational STACCATO study, 28 inflammatory markers associated with increased cardiovascular risk, such as sVCAM-1 (soluble vascular adhesion molecule-1), were associated with HIV RNA replication and decreased with HAART initiation. In a separate study by the SMART/INSIGHT and D.A.D. working groups, 29 abacavir, found in some HAART regimens, was associated with an increased risk of allcause cardiovascular disease, which included stroke. The relationship between HAART and long-term stroke risk requires further investigation.
There may be important risk factors that confound the relationship between stroke and HIV such as injection drug abuse with cocaine, excessive alcohol use, or poor medication adherence. Given that the majority of the HIV1 cohort with strokes was HAART-treated, it is unlikely that the strokes were caused by opportunistic infections; however, a fraction of the HIV1 participants with stroke had lower than expected CD4 counts and should be considered immunosuppressed. The MACS represents mostly HAART-treated adults, a situation that almost certainly mimics the clinical scenario in most highincome settings.
Our study had several limitations. Stroke ascertainment in this cohort was partially dependent on self-reported events that were later verified by physicians and study investigators. In some cases, medical records from the patient could not be verified by the study site and diagnosis could only be based on the participant's provided information. Although a majority of strokes received an ICD-9 designation by the treating physician, there were several events that were not subclassified by mechanism or stroke type. We were unable to report the number of strokes by subtype and compare them with the original Framingham Heart Study cohort; nonetheless, the FRS-S is useful for general risk of stroke and not specific to subtype. Assessments related to stroke Table 3 Selected clinical studies of stroke in HIV-infected adult patients performed in the HAART era with ‡10 HIV-infected stroke patients (July 1996 severity, functional outcome, and neuroimaging confirmation were not consistently available in the MACS. This is true in most study cohorts of HIV1 individuals in whom vascular disease, particularly stroke, was not a priority condition to study. Because MACS began studying self-reported strokes in detail in 2006, it is possible that strokes that occurred earlier in the HAART era were not all ascertained. However, given our definition of the HAART era as 1996 and beyond, the inclusion of stroke in 2006 on interview forms is still appropriate for assessment of risk at the required time point of 10 years earlier. Some MACS participants had a stroke event before 2006, and pre-HAART era years were included in their risk period. This occurred in a minority of cases. Diabetes mellitus was ascertained regularly from April 1999 onward and at the time of the participant's entry into the MACS. Notably, a participant who developed diabetes between his study entry and April 1999 may not have the date of diabetes diagnosis recorded with the MACS cohort until 1999. This would lead to underestimation of his FRS-S because points would not have been ascribed for diabetes in that individual in that timeframe.
Our study was limited to adult MSM. It is possible that our findings are not generalizable to other HIV1 populations such as women, or persons with other high-risk behaviors for stroke such as injection drug abuse. There are more African Americans in the MACS compared with the Framingham Heart Study, which may lead to a differing baseline risk of stroke. Race is not part of the FRS-S but has been studied in cardiovascular disease prediction. 30 Also, access to care may be better among MACS participants.
This study had several strengths. The MACS has the advantage of enrollment of both HIV1 and HIV2 MSM in the same prospective cohort study and does not derive its control group from other databases or registries. Many other cohorts lack an HIV2 control group, making it difficult to discern the relative contributions of age, other HIV-related risk factors, and HIV infection. The number of strokes in the MACS is among the highest of any HIV1 cohort with welldescribed cardiovascular risk factor variables and HIV status information. Despite the high number of reports suggesting that HIV is an important risk factor for stroke, the number of reported patients with both HIV and stroke is small. Other studies have survival bias, such that an increased number of HIV1 individuals experiencing stroke in the HAART era may be inaccurately equated with HIV as a risk factor for stroke. In the MACS, we had the unique opportunity to retrospectively calculate the FRS-S in participants 10 years before stroke events. Because events were ascertained prospectively, there is no recall bias. Also, our finding that some individuals with stroke had an FRS-S of zero suggests that there are particular individuals at high risk, which is difficult to predict using standard scores.
Adjustment and calibration of the FRS-S may be of high future utility in the HIV1 adult population. 31234 Follow-up of existing cohorts, with dedicated attention to vascular outcomes, is imperative to understand the accuracy of stroke prediction in HIV1 populations with various baseline risks.
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